Broader markets outperform, Core Education jumps 23%

The BSE mid-cap index has advanced 0.85% or 6,194 and the small-cap index is up 1.66% or 96 points at 5,901.

SI Reporter Mumbai
Last Updated : Apr 01 2013 | 1:14 PM IST
The markets are trading flat in noon trades Monday. The Sensex is up 18 points at 18,854 and the Nifty is higher by 11 points at 5,694. The broader markets are however outperforming the benchmark indices.

The BSE mid-cap index has advanced 0.85% or 6,194 and the small-cap index is up 1.66% or 96 points at 5,901.

CORE Education & Technologies is the top Midcap gainer. The stock has jumped over 23% to Rs 63.

Also Read

Coromandel International, HMT, Indiabulls Power, PC Jeweller, Mahanagar Telephone Nigam, Tata Teleservices (Maharashtra) and Welspun Corp are also buzzing in trades, up 5-8% each.

Shree Ganesh Jewellery House jumped 7% to Rs 96.25 after the company said it allotted 41.44 lakh equity shares to its promoters at Rs 150 each.

Aurobindo Pharma has surged 6% to Rs 154, extending its previous day’s over 12% rally after US Food and Drug Administration’s (USFDA) has lifted the import alert for non-sterile products manufactured in its UNIT-VI cephalosporin facility based in Hyderabad.

TRF has surged over 11% to Rs 159 in early morning deals on NSE after the company received Rs 360 crore orders from Nabinagar Power Generating Company Private Limited, a joint venture Company of NTPC and Bihar State Power (Holding) Company.

From the real estate pack, HDIL has surged 7.3% at Rs 49.65. The stock has managed to recover 12% from its all time low of Rs 43.65 which it touched on March 26, 2013. This was mainly due to the rating downgrade following a debt pile up and delay in its project. CARE downgraded two tranches of NCDs worth Rs 1,894 crore from 'BBB+' to 'D' grade and another worth Rs 200 crore from A3+ to 'D' grade. D means instruments that are in default or going to default soon.

On the losing side, Novartis India has dipped almost 7% to Rs 558, also its 52-week low on BSE, after the Supreme Court has denies cancer drug patent to the company.

The overall breadth of the BSE mid-cap index is healthy as 171 stocks are advancing while 78 are declining.

According to Gaurav Dua, Head of Research, Sharekhan, “Mid caps have been beaten down severely in the past few weeks and thus have bounced back sharply from the oversold levels. Mid caps with weak fundamental would not sustain the rally but the interest in quality mid cap names is reasonably high among smart clients”.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 01 2013 | 12:50 PM IST

Next Story